CLINICAL_TRIALS
withdrawal
· 2017-03-03
Clinical Trial Update: Intranasal Ketamine for Late-Life Depression and Suicidal Ideation [Phase 4]
Summary
A Phase 4 clinical trial evaluating intranasal esketamine for late-life depression and suicidal ideation has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Depression, Suicide | Phase 4 | Status: WITHDRAWN